Phase III randomized trial of interferon-alfa2b alone versus interferon-alfa2b plus thalidomide in patients with previously untreated metastatic or unresectable renal cell carcinoma
Latest Information Update: 18 Sep 2021
Price :
$35 *
At a glance
- Drugs Interferon alpha-2b; Thalidomide
- Indications Renal cancer
- Focus Biomarker; Therapeutic Use
- 13 Oct 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 05 Feb 2009 Biomarkers information updated
- 03 Sep 2005 New trial record.